Skip to main content
. 2020 Feb 10;4(3):514–524. doi: 10.1182/bloodadvances.2019000919

Figure 1.

Figure 1.

Gilteritinib activity against activating and TKI resistance-causing FLT3 mutations. (A) Gilteritinib IC50 levels for proliferation of Ba/F3 cells expressing activating FLT3 TKD mutations. Error bars represent standard deviation (SD) of 3 or more independent experiments. (B) Gilteritinib IC50 levels for proliferation of Ba/F3 cells expressing FLT3-ITD TKD mutations previously associated with FLT3-TKI resistance. Error bars represent SD of 3 or more independent experiments.